Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
- Conditions
- Vaccine RefusalCovid19
- Registration Number
- NCT04871776
- Lead Sponsor
- Brigham and Women's Hospital
- Brief Summary
This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upcoming primary care clinic visit, will be randomized to one of three messaging arms: 1) "why" messaging, 2) "how" messaging, or 3) standard of care ("usual care"). Messages will be sent via the electronic patient portal a few days in advance of their office visit. The primary outcome will be the rate of booster vaccination at the targeted visit. The secondary outcome will be the rate of receipt of a COVID booster vaccine within 6 weeks of the targeted visit. Subgroup analyses to assess for any association of patient characteristics with intervention responsiveness will be exploratory.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3671
- Patients in the Mass General Brigham system
- Aged 18 and older
- Are eligible for the COVID booster vaccine but have not received a dose at time of upcoming primary care clinic visit
- Documented allergy to a COVID vaccine or its components
- Home address outside of Massachusetts
- Did not receive full set of primary COVID-19 vaccination series
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Number of Participants Who Received a Booster Vaccination Through the Targeted Visit 2-5 days Number of participants who received one dose of a COVID booster vaccine between randomization through the date of the scheduled visit, determined through electronic health records.
- Secondary Outcome Measures
Name Time Method Number of Participants Who Received a Booster Vaccination Within 6 Weeks of the Targeted Visit 6 weeks after the target visit Number of participants who received one dose of a COVID booster vaccine between randomization through 6 weeks after the targeted visit, determined through electronic health records.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Mass General Brigham
🇺🇸Boston, Massachusetts, United States
Mass General Brigham🇺🇸Boston, Massachusetts, United States